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MAIN TEXT Introduction
Ewing sarcoma (EwS) represents the second most common bone and soft tissue cancer in children and adolescents, which potentially arises from neuroectodermal or mesodermal mesenchymal stem cells 1, 2 . In fact, EwS tumors display a largely undifferentiated and 'stemness' phenotype, which is believed to contribute to its clinical aggressiveness 1 .
Genetically, the hallmark of EwS are chromosomal translocations generating chimeric proteins through fusion of the EWSR1 (Ewing sarcoma breakpoint region 1) gene to variable members of the ETS (E26 transformation specific) family of transcription factors, in 85%
FLI1 (Friend leukemia virus integration 1) [3] [4] [5] . These EWSR1-ETS fusion oncoproteins act as aberrant transcription factors that promote tumor initiation and progression by massively rewiring the cellular transcriptome and spliceosome 1, 6, 7 .
Sixty to 75% of EwS patients benefit from multimodal therapy 2, 8 . Consequently, >30% of patients show limited response to treatment, which is often first noted based on assessment of histological response after neoadjuvant chemotherapy 9 . Since limited treatment response may be associated with early relapse 10 , upfront identification of high-risk patients is essential to assign them to adequate treatment regimens. Despite several clinicopathological features (such as tumor volume, histological response, tumor site and age at diagnosis) have been associated with high-risk disease, so far the presence of metastasis at diagnosis remains the major factor for risk-stratification in EwS patients 11 . However, for patients with localized disease, risk prediction remains difficult as no bona fide prognostic biomarkers independent from metastasis are available 1, 12 .
A prior report indicated that stemness in EwS may be mediated via EWSR1-FLI-induced expression of SOX2 (sex determining region Y box 2) 13 -a well-known stemness gene overexpressed in many cancers 14 . We therefore explored in the current study the expression pattern of SOX2 in two independent EwS cohorts and investigated whether it may serve as biomarker for outcome prediction in EwS.
We show that SOX2 is expressed only in ~16-20% of EwS tumors, which is associated with very poor patient outcome independent of metastasis. Moreover, high expression of SOX2 significantly correlates with tumor relapse. Our findings suggest that detection of high SOX2
expression by immunohistochemistry or RNA-based techniques may constitute a broadly available biomarker for risk-stratification even for patients with localized disease.
MATERIALS AND METHODS

Study populations
For this study, a retrospective test-cohort and a prospective validation-cohort were analyzed.
Patients' characteristics of both cohorts are listed in Table 1 .
The study population of the test-cohort consisted of 189 EwS patients whose molecularly confirmed and retrospectively collected primary tumors were profiled on the mRNA level by gene expression microarrays in previous studies [15] [16] [17] [18] . To assemble this mRNA-cohort, microarray data generated on Affymetrix HG-U133Plus2.0, Affymetrix HuEx-1. 
Statistical analyses
Statistical analyses were carried out with SPSS 19 (IBM Corporation, Armonk, NY) and SAS 9.2 (SAS Institute, Cary, NC) as described 21 . Overall survival (OS) was estimated by the Kaplan-Meier method. OS time was defined as the interval between the date of diagnosis and the date of last follow-up or death. Group comparisons were calculated by log-rank test.
Multivariate analyses were carried out by applying the Cox proportional hazard method.
Differences in proportions between groups were evaluated by chi-square or Fisher's exact test. Significance level was set at P<0.05 for two-sided testing. No alpha corrections were carried out for multiple testing. Outcome was analyzed on an exploratory basis.
RESULTS
SOX2 is expressed in a subset of EwS patients and correlates with overall survival (OS)
SOX2 is a well-known transcription factor involved in stemness during normal development and cancer 14 Indeed, only 20.1% (38/189) of samples exhibited moderate to strong SOX2 expression levels (Fig. 1A) . Stratifying our mRNA-cohort by a cut-off of the 80 th percentile of SOX2 expression in SOX2-low or -high cases, we noted that patients with high intratumoral SOX2 expression had a worse OS than patients with low SOX2 expression (P<0.0001) (Fig. 1B) .
To validate this finding on the protein level, we stained an independent validation TMA-cohort comprising 141 EwS cases with an anti-SOX2-antibody with proven specificity for EwS (Fig. S3B) . Patient characteristics are reported in showed £10% positive nuclei (classified as SOX2-low) while only a small subset of patients (15.6%, 22/141) had >10% positive nuclei (classified as SOX2-high) (Fig. 1C,E) . Strikingly, applying the cut-off of >10% SOX2 positive nuclei fully confirmed the strong association of SOX2 expression with poor OS of EwS patients (P=0.0004) (Fig. 1D) .
Collectively, these results demonstrate, for the first time, that high SOX2 expression is not a common feature of EwS, but that its high mRNA and protein levels may serve as a biomarker for outcome prediction.
High SOX2 expression is a major risk-factor for tumor associated-death independent from metastasis in EwS
To identify factors that may influence patients' prognosis, we performed a multivariate analysis in our validation TMA-cohort as here additional clinicopathological information beyond OS were available. Interestingly, multivariate analysis revealed that the major risk- 
SOX2-high expression significantly correlates with tumor relapse
Next, we investigated whether the correlation between SOX2-high expression and OS is associated with histological response, high tumor volume (³200 ml), and relapse, which are risk-factors for worse outcome 12, [22] [23] [24] .
In our TMA-cohort, data on histological response, tumor volume and tumor relapse were available for 84, 136 and 141 patients, respectively ( Table 4) . Our data did not show an association of SOX2-high expression with histological response (Table 4) . However, we observed a tendency for an association between SOX2-high and tumor volume. In fact, 58.3%
of patients with high SOX2 expression had a tumor volume ≥200 ml compared to 41.7% patients with low SOX2 expression (P=0.23) ( Table 4) . Since the association of SOX2 and higher tumor volume suggested a role for SOX2 in EwS growth, we performed functional in vitro and in vivo experiments using an established EwS cell line model (POE) for which we generated a derivate with a doxycycline (dox-)inducible shRNA against SOX2. The results
showed that knockdown of SOX2 in POE cells led to strong reduction in cell proliferation, clonogenic growth and anchorage-independent growth compared to cells expressing a nontargeting control shRNA (Fig. S2) . Consistently, dox-induced silencing of SOX2 in POE cells xenografted in immunocompromised NSG mice significantly reduced tumor growth (Fig. S3) .
In addition, we noted a striking correlation of SOX2-high expression with tumor relapse (P=0.001) ( Table 4) . While only 38.7% of patients with SOX2-low expression had relapse, recurrence occurred in 77.3% of patients with SOX2-high expression (Table 4) , which may explain the observed poor outcome for these patients. In agreement with these observations, gene set enrichment analysis (GSEA) in our mRNA cohort showed that genes co-expressed with SOX2 in primary EwS tumors are involved in stemness, proliferation, dedifferentiation and cancer relapse (Fig. S2A, Supplementary Table 1) .
Collectively, these results suggest that SOX2-high expression may confer worse outcome to EwS patients by contributing to tumor growth and relapse.
DISCUSSION
Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time range of 2-10 years 25 . Clinical prognostic markers such as primary dissemination, tumor site, size, age and histological response to chemotherapy are established risk-factors used for therapeutic stratification 25 . However, especially for patients with localized disease and otherwise no apparent risk-factors, risk prediction is challenging 26 .
Although there is broad consensus that clinical management will benefit from prognostic or predictive biomarkers that can guide therapeutic decisions, there are currently no bona fide biomarkers available that may help predicting tumor relapse and outcome of patients with EwS 1, 12 .
In this study, we report, for the first time, that high mRNA or protein expression of SOX2 is a stratification risk-factor for ~16-20% of EwS patients with poor outcome. Notably, multivariate analyses including either all or only patients with localized disease demonstrated that SOX2-high expression represents an independent and strong risk-factor for EwS patients.
In line with our findings in EwS, high expression or amplification of SOX2 has been reported to correlate with poor survival in breast, colorectal, esophageal, laryngeal, endometrial and ovarian carcinoma 14, [27] [28] [29] [30] . Similarly to EwS, SOX2 is highly expressed in a subset of patients with lung adenocarcinoma and was found to be an independent predictor of poor survival 31 .
Prior reports suggested that SOX2 may constitute a direct EWSR1-FLI1 target gene 13, 32 .
Surprisingly, we found that the vast majority of molecularly confirmed EwS cases do neither express SOX2 on the mRNA nor on the protein level, suggesting that the mode of regulation and the functional role of SOX2 may be more complex than anticipated.
In our TMA-cohort, SOX2-high expression showed a correlation with tumor relapse (P=0.001), which likely explains the poor outcome of these patients. In support of our findings, it has been shown in sinonasal carcinomas that patients with SOX2 amplification had a significantly higher rate of tumor recurrences than those without SOX2 amplification 33 .
However, in our TMA-cohort 38.7% of patients with SOX2-low expression showed relapse suggesting that in this subset of patients a different driver might mediate tumor relapse.
Although the correlation between SOX2-high and tumor volume was not significant in our TMA-cohort, in line with previous reports in EwS 13, 34 , our in vitro and in vivo results confirmed a functional role of SOX2 in EwS cell proliferation and tumor growth suggesting that a larger cohort might enable validation of this correlation in EwS patients. In agreement, our GSEA in primary EwS indicated that SOX2-high tumors are enriched for gene signatures involved in dedifferentiation, proliferation and stemness, which may promote tumor relapse.
Interestingly, GSEA also revealed that SOX2 co-expressed genes overlap with genes involved in relapse of malignant melanoma -a tumor of neuroectodermal origin 35 , which is also proposed for EwS 36 . In support of these data, GSEA of differentially expressed genes upon SOX2 knockdown in three SOX2-high EwS cell lines demonstrated a significant upregulation of gene signatures involved in differentiation-related processes such as neurite outgrowth, integrin cell surface interaction, and components of the basement membrane (Fig. S1B, 
Supplementary Table 2).
Despite the exploratory nature of this study, SOX2-high expression may constitute the first promising biomarker for outcome prediction and stratification of high-risk EwS patients with localized disease, which is readily available due to standardized assessment by qRT-PCR and/or IHC. Moreover, our results suggest that SOX2-high EwS patients may benefit from an alternative therapy that could be administered upfront. Therefore, we recommend validation of these observations in additional prospective studies and to experimentally elucidate the precise molecular role of SOX2 in EwS. Table 1 . Patient characteristics of the mRNA-cohort (n=189) and TMA-cohort (n=141). * all extremity localizations are non-axial; ** good response defined as <10% viable tumor cells; NA, not available. Table 2 . Multivariate analysis in all patients of the TMA-cohort (n=141). Met, metastases. * reference (R). Table 3 . Multivariate analysis in patients with localized disease from the TMA-cohort (n=87). Table 4 . Correlation of SOX2 immunoreactivity with metastasis, histological response, tumor volume and relapse in the TMA-cohort (n=141). Table 5 . Correlation of SOX2 mRNA with metastasis in the mRNA-cohort (n=76). Information on the status of metastasis was only available for a subset of the test cohort.
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